Recent Updates
Recently added Catalysts

Period A

Phase 2

OSA | Small Molecules | Respiratory |Apnimed, Inc.|Trials Updated: Nov 15, 2023

Period A development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Mar 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment25

FDA Designations

No designations recorded

Period A clinical trials

Period A · 1 trial · 2 indications

Phase 2 1
NCT05793684AD816 Crossover StudyOSA
COMPLETED25 Analytics
PHASE2COMPLETED
AD816 Crossover Study
OSAUnlock trial analytics

Study Endpoints

Primary Endpoints

Apnea-hypopnea index (AHI) 4%, AD816 vs. Placebo
14 days of treatment dosing per crossover arm (collected at the end of treatment dosing per crossover arm)

Apnea-hypopnea index based on 4% hypopnea desaturation

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Order: Period A, Period B, Period CEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Order: Period B, Period C, Period AEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Order: Period C, Period A, Period BEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Order: Period A, Period C, Period BEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Order: Period B, Period A, Period CEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Order: Period C, Period B, Period AEXPERIMENTALThe sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).

Interventions

NameTypeDescription
Period ADRUGWeek 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period BDRUGWeek 1: AD816 low dose; Week 2: AD816 high dose
Period CDRUGWeek 1: Placebo + Placebo; Week 2: Placebo + Placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: 1. Between 18 to 75 years of age, inclusive, at the Screening Visit 2. PSG criteria (V2 only) 1. AHI4 (Hypopneas defined by 4% oxygen desaturation) of 10-45, inclusive 2. ≤25% of events are central or mixed apneas 3. PROMIS Fatigue or sleep related impairment or sleep dis...

Countries:United States
Unlock Eligibility Criteria